-
Mashup Score: 1Multi-dose phase of 64Cu/67Cu-SAR-bisPSMA study begins in mCRPC - 19 hour(s) ago
Among all patients treated in the study to date, 60% demonstrated a PSA reduction of greater than 35%, and 27% demonstrated a PSA reduction of greater than 80%.
Source: www.urologytimes.comCategories: General Medicine News, UrologyTweet
-
Mashup Score: 0Black Men Face Highest Incidence of Prostate Cancer in the UK - Renal and Urology News - 4 day(s) ago
However, for advanced-stage prostate cancer, incidence similar to that of White men
Source: www.renalandurologynews.comCategories: General Medicine News, UrologyTweet
-
Mashup Score: 2
In an interview with Targeted Oncology, Rohan Garje, MD, discussed how mutations such as TP53, RB1, and PTEN impact overall survival in patients with metastatic prostate cancer.
Source: www.targetedonc.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 0
Dan S. Childs, MD, discusses treatment with olaparib and abiraterone in metastatic castration-resistant prostate cancer.
Source: www.onclive.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 14
This study examines 2 randomized clinical trials to assess the efficacy and safety of the oral gonadotropin-releasing hormone antagonist relugolix with radiotherapy for treating prostate cancer.
Source: jamanetwork.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 0
Dan S. Childs, MD, discusses treatment with olaparib and abiraterone in metastatic castration-resistant prostate cancer.
Source: www.onclive.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 32
This study examines 2 randomized clinical trials to assess the efficacy and safety of the oral gonadotropin-releasing hormone antagonist relugolix with radiotherapy for treating prostate cancer.
Source: jamanetwork.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 1NCCN Recommends First AI Prognostic Tool in Prostate Cancer - 13 day(s) ago
The National Comprehensive Cancer Network has included ArteraAI in its clinical practice guidelines as a predictive test for localized prostate cancer.
Source: www.targetedonc.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 42024 Virtual Summit | ZERO Prostate Cancer - 16 day(s) ago
Register for the 2024 Virtual Education Summit. Take part in live and on-demand sessions featuring the latest prostate cancer treatments, sexual health, and more.
Source: zerocancer.orgCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 1
The systematic review and meta-analysis provided clinical trial as well as real-world estimates of the association of performance status with mortality in mCRPC.
Source: www.renalandurologynews.comCategories: General Medicine News, UrologyTweet
The phase 1/2a SECuRE trial of 64Cu/67Cu-SAR-bisPSMA in mCRPC has progressed to the multi-dose phase of the study following promising safety and preliminary efficacy data from patients treated at the highest single-dose level of 12 GBq. #pcsm Read more: https://t.co/4cegoJexHs